Peptide News Digest

Kentucky Bars Six Compounded Peptides, Wegovy Pill Prices in Australia, Denmark's Eye Injury Payouts

Kentucky bars pharmacies from compounding BPC-157 and five other peptides, Australia prices the Wegovy pill, and Denmark pays 31 people for vision loss.

12 stories · Covering regulatory, industry, clinical-trials, research

Editor's Note

About three weeks after HHS said it would not act against pharmacies compounding six unapproved peptides, Kentucky's pharmacy board said the federal policy changes nothing in Kentucky, where none of the six has ever met the state's ingredient rules. That matters for Hims & Hers, which plans to add BPC-157 and TB-500 to Peptides+, and it shows that state boards can still say no. Outside the United States the gray market keeps growing: New Zealand Customs has detained 840 peptide parcels so far this year, more than twice 2025's total, and South Korea is going after people who resell GLP-1 drugs they bought abroad. Legal access is widening at the same time. GPs in Australia can now prescribe the Wegovy pill at A$260 to A$395 a month, and Innogen has licensed its China-approved GLP-1 drug for parts of Africa, Latin America, the Middle East, and Eastern Europe. Denmark's payouts to 31 people with a rare cause of vision loss are compensation decisions, not proof that the drugs caused it, and Novo disputes the link. Two records studies, in asthma and congenital heart disease, favor GLP-1 drugs, and both carry the usual caution that patients who start a new drug can differ from those who don't.

Kentucky Board of Pharmacy Bars Compounding of BPC-157, TB-500, and Four Other Peptides Despite the HHS Enforcement Policy

The Kentucky Board of Pharmacy voted on November 18 to enforce its compounding rule as written and to refuse waivers for BPC-157, TB-500, Epitalon, Semax, KPV, and MOTS-c, the six peptides covered by HHS's October 30 enforcement discretion policy. In a November 19 compliance alert, the board said none of the six has a USP or National Formulary monograph, is part of an FDA-approved drug, or is on FDA's 503A bulks list, so compounding them in or into Kentucky "has never been authorized." In-state and out-of-state pharmacies must not compound, dispense, or ship them to Kentucky patients, and violations can cost a pharmacy its license or bring a fine. The board said it will notify licensees if FDA adds any of the six to its bulks list.

South Korea Cracks Down on Reselling GLP-1 Drugs Bought Abroad After Easing Its Personal Import Limit

South Korea's Ministry of Food and Drug Safety said on November 19 that it has started a nationwide crackdown on online sales, brokering, and advertising of GLP-1 obesity drugs, including secondhand trading, and warned that people who bring the drugs in for their own treatment break the Pharmaceutical Affairs Act if they resell or give them away, The Korea Times reported. The ministry set up a reporting center and task force and plans to seek investigations and file criminal complaints. The move follows the November 12 rule letting travelers bring in a three-month supply prescribed overseas. Health Insurance Review and Assessment Service data show 1,501,161 Mounjaro prescriptions in Korea from its August 2025 launch through May 2026, with monthly prescriptions rising from 18,579 to 273,140.

Denmark Pays 15 Million Kroner to 31 People With NAION Vision Loss After Wegovy or Ozempic

The Danish state has paid a total of 15 million Danish kroner to 31 people who developed NAION, a rare eye condition that can cause permanent vision loss, after taking Novo Nordisk's Wegovy or Ozempic, Bloomberg reported on November 19. Of 94 claims, 29 were rejected and 34 are still under review, and the state, not Novo, pays the awards. Novo said no causal relationship between the drugs and the disease has been established. The FDA added a NAION warning to every GLP-1 drug's label earlier this month.

Australian GPs Can Prescribe the Wegovy Pill From November 20 at A$260 to A$395 a Month, Without PBS Subsidy

Novo Nordisk's Wegovy pill became available on private prescription in Australia on Friday, November 20, newsGP reported, with recommended prices of A$260 for the 1.5 mg strength, A$270 for 4 mg, A$280 for 9 mg, and A$395 for the 25 mg maintenance dose. The dose rises every 30 days, and the pill must be taken on an empty stomach with a small sip of water at least 30 minutes before food or other medicines. Neither the pill nor injectable Wegovy is on the Pharmaceutical Benefits Scheme for weight management. Dr Mark Mellor, who chairs the RACGP's obesity management group, said "the best choice is one that suits a person's health needs and one that they can manage over time."

Innogen Licenses Its GLP-1 Drug Efsubaglutide Alfa to Abu Dhabi's Arcera in a Deal Worth More Than $1 Billion

Innogen Pharmaceuticals granted Arcera Life Sciences exclusive rights to sell efsubaglutide alfa, a long-acting GLP-1 fusion protein approved in China for blood sugar control in adults with type 2 diabetes, in selected countries in Africa, Eastern Europe, Latin America, and the Middle East, the companies announced on November 19, Pharmaceutical Executive reported. Innogen gets $38 million in upfront and near-term payments, including $15 million upfront, plus sales milestones and tiered royalties of up to double-digit percentages, for a total potential value above $1 billion. Arcera will handle regulatory filings and sales, and the drug is not approved for obesity.

Reuters: Worldpanel Says Households With a GLP-1 User Spent More Than £1 Billion Less on Groceries Than Expected

British households with a GLP-1 user spent about £389 a year less on groceries than expected, adding up to more than £1 billion, Worldpanel by Numerator said, Reuters reported on November 19. The share of households with a user rose from 6.3% in February to 8.5% in August, pills already account for 11.2% of users after their June approval, and men make up 32% of users, up from 23%. User households cut alcohol and crisps spending 15% more than other households and bought 30% more frozen ready meals by volume. Worldpanel expects more than 10% of British households to include a user in 2027.

The Spinoff: New Zealand Customs Detained 840 Peptide Parcels Through September, Up From 370 in All of 2025

New Zealand Customs detained 840 peptide parcels this year through September, compared with 370 in 2025, The Spinoff reported in a November 20 roundup. The NZ Drug Foundation's drug-checking service has received 67 peptide samples so far this year, up from one in 2023, six in 2024, and 11 in 2025, executive director Sarah Helm said. The Spinoff also cited The Post's count of more than 25 local peptide websites shut down so far. A Ministry of Health count reported by RNZ earlier this month put border interceptions at 398 parcels of peptides, suspected peptides, or SARMs in the first half of the year.

UCLA's Priscilla Hsue Wins a $6.3 Million NIH Grant for the Olympic-HIV Trial of an Oral GLP-1 Drug

UCLA cardiologist Dr. Priscilla Hsue received a $6.3 million R01 grant from the National Heart, Lung, and Blood Institute to lead Olympic-HIV, a multicenter, randomized, placebo-controlled trial of an oral GLP-1 drug in adults aged 40 and older with HIV and at least one cardiovascular risk factor, UCLA Health announced on November 18. Over 52 weeks, the trial will use imaging and blood tests to measure arterial inflammation, coronary plaque, immune activation, and other markers. People with HIV have higher rates of heart disease, driven in part by chronic inflammation. The release does not name the drug or the planned enrollment.

Baylor Records Study: Tirzepatide Starters Had Fewer Severe Asthma Attacks Than Tezepelumab Starters

In electronic health records of 2,779 adults without diabetes who had obesity-associated, moderate-to-severe asthma and a severe attack in the prior year, those who started tirzepatide had a lower weighted hazard of another severe attack than those who started the biologic tezepelumab (hazard ratio 0.41, 95% CI 0.24 to 0.70), while semaglutide starters had a similar rate (0.99). Both GLP-1 groups reached a 10% drop in BMI sooner, used fewer rescue inhalers, and had fewer respiratory-related visits, Baylor College of Medicine researchers report in the American Journal of Respiratory and Critical Care Medicine. The study was observational, and the authors say clinical trials are needed.

Records Study of Adults With Congenital Heart Disease Links Semaglutide to Lower Death Rates, but a Warning Signal Limits the Finding

Among adults with congenital heart disease and type 2 diabetes in the TriNetX network, 1,422 who started semaglutide and 1,422 matched patients who started a DPP-4 inhibitor were followed for three years. Deaths were 7% versus 12% (hazard ratio 0.66), and hospitalizations and emergency visits were also lower with semaglutide, but heart attacks and arrhythmias were not. A negative control outcome, which should not differ between the groups, was raised in every analysis, so the authors, writing in the American Journal of Cardiology, say patients who started semaglutide may differ in how they use health care and call the results hypothesis-generating.

Brazilian-U.S. Team's Annexin A1 Peptide Ac2-26 Protected Lab-Grown Human Retinas From High-Glucose Damage

Researchers at the Federal University of São Paulo, São Paulo State University, and the University of Colorado Anschutz grew retinal organoids and retinal ganglion cells from human stem cells and exposed them to high glucose and inflammation, as in diabetic retinopathy. The peptide Ac2-26, a fragment of the anti-inflammatory protein annexin A1, reduced cell death, Müller cell gliosis, and mitochondrial oxidative stress, effects tied to the FPR2 receptor and the p38/NOX4 pathway, the team reports in Biomedicine & Pharmacotherapy; News-Medical covered the work on November 19. The work was done in lab-grown tissue only, and the researchers say animal and human studies come next.

Gansu Mouse Study: Curcumin Linked to the Staph-Blocking Peptide RIP Healed MRSA-Infected Wounds Better Than Vancomycin

Gansu Agricultural University researchers attached curcumin to RNAIII-inhibiting peptide (RIP), which interferes with how Staphylococcus aureus coordinates infection. In lab tests, the conjugate cut MRSA biofilm formation by 71% and reduced the mass of 48-hour-old biofilms by 66.8%, with low toxicity to mouse fibroblast cells. In mice with full-thickness MRSA-infected wounds, it lowered inflammatory and bacterial virulence markers and produced better healing than vancomycin, the team reports in Biomolecules. The authors say its mechanism and the risk of resistance still need study.